Loading…
← CockpitCompetitor Analysis › 000963.SZ Huadong Medicine Co., Ltd. Class AOpen in the cockpit ↗

Huadong Medicine Co., Ltd. Class A000963.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese pharma company spanning prescription drugs, diabetes/endocrine care and medical aesthetics (fillers, devices).

≈ A Chinese Allergan-meets-Novo Nordisk generics hybridMomentum strong 67
Mkt cap
$6.69B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$65.7M
20-day average traded
Fwd P/E
12.5×
forward earnings
ROIC−WACC
+6.9 pp
WACC 6.2%
Hurdle
-9 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥25.62
1D+0.1%
1W-3.5%
1M-4.1%
3M-13.3%
6M-18.1%
YTD-35.1%
1Y-37.3%
ATR %2.2%
52w lowhigh41.5% off high

What Huadong Medicine does

Chinese pharma company spanning prescription drugs, diabetes/endocrine care and medical aesthetics (fillers, devices).

Resells other makers' drugs to hospitals and pharmacies, which brings in the most revenue at thin margins, while its own prescription drugs, including diabetes treatments, and its aesthetics products carry most of the profit. Aesthetics are mostly paid for by consumers rather than insurance, which keeps that line outside government drug-price controls.

In one line: A Chinese Allergan-meets-Novo Nordisk generics hybrid.

Products and services

  • Prescription pharmaceuticals
  • Medical aesthetics (fillers/devices)
  • Diabetes/endocrine drugs
  • Pharma distribution

Customers

  • Hospitals
  • Aesthetic clinics
  • Pharmacies

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals & aesthetics
  • Branded drugs, aesthetic devices…

What could go right

  • China aesthetics market growth
  • Diabetes drug portfolio expansion

What could go wrong

  • Drug price cuts (VBP)
  • Aesthetics price competition

Moat: narrow (brand, distribution). Established hospital sales network plus a fast-growing aesthetics distribution and device business.

Headquarters: Hangzhou, China · Founded: 1993 · Employees: 19,095

Named competitors

Huadong Medicine at a glance

Size Huadong Medicine (000963.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.69B, the 350th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥25.62 on 18 Nov 2026.

Performance Over six months the shares fell 18.1%, against -1.8% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 2.4% over the last twelve months (peer median +16.4%); the operating margin is 9.2% (peer median 14.1%).

Valuation It trades at 12.5× forward earnings against a peer median of 21.6× (3rd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.9 points above its cost of capital (6.2% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 99000963.SZ 85
Six months, rebased to 100: Huadong Medicine against the median of its 20 peers (local-currency closes).

Huadong Medicine financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥44.0BCN¥43.4BCN¥41.7BCN¥40.4BCN¥37.5B
Revenue growth—+4%+3%+8%—
Gross profitCN¥14.4BCN¥13.4BCN¥13.3BCN¥12.6BCN¥11.5B
EBITDAn/aCN¥5.16BCN¥5.18BCN¥4.41BCN¥3.86B
Net incomeCN¥3.44BCN¥3.41BCN¥3.51BCN¥2.84BCN¥2.50B
Free cash flowCN¥2.30BCN¥2.74BCN¥2.07BCN¥2.42BCN¥1.29B
Capital expenditureCN¥1.24BCN¥1.57BCN¥1.73BCN¥1.61BCN¥1.19B
Total debtCN¥5.67BCN¥5.03BCN¥5.65BCN¥3.74BCN¥3.70B

Quarterly statements and history in the cockpit →

Huadong Medicine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%ALKEM000999ORKA0126Z0BLTE9926BANBBIOCON6821688331IBRXCYTKMIRMCORTSUPNKNSAGRFLGND000963.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Huadong Medicine is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×60×ALKEM000999APTXBANBBIOCON68216883314528CORTSUPNKNSA000963.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Huadong Medicine is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%ALKEM000999APTX688331SUPNKNSALGND000963.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Huadong Medicine is the large dot.

Huadong Medicine competitors and peer comparison

Head to head with its named competitors (000963.SZ vs 1177.HK vs 300896.SZ vs 688363.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Huadong Medicine 000963.SZ$6.69B-18%+2%9%12.5×-3.9%
Sbp 1177.HK$12.2B+5%+15%30%17.5×-5.7%
IMEIK Technology Development 300896.SZ$3.66B-25%-7%45%22.4×17.5%
Bloomage Biotechnology 688363.SS$2.27B-21%-22%5%52.0×19.0%

How Huadong Medicine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Huadong Medicine against its 20 peers (data as of 18 Nov 2026)
Measure000963.SZPeer medianRank in peer set
1-month return-4.1%+1.7%9th lowest of 21
6-month return-18.1%-1.8%6th lowest of 20
Distance from 52-week high-41.5%-20.5%8th lowest of 21
Revenue growth (TTM)+2.4%+16.4%4th lowest of 18
Operating margin9.2%14.1%6th lowest of 19
Forward P/E12.5×21.6×3rd cheapest of 15
Growth the price implies (Req g, 7 yrs)-3.9%6.6%4th least demanding of 11
Growth delivered (Del g)+5.3%+12.3%2nd lowest of 11
Hurdle (Req g minus delivered)-9.2 pp-11.9 pp6th least demanding of 11
ROIC minus cost of capital+6.9 pp-0.8 pp5th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
RemeGen 688331.SSChina$6.28B-24%+272%61%10.8×1.1%+303.3%
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%

Questions

Who are Huadong Medicine's main competitors?
Named competitors: Sino Biopharm (1177.HK), Imeik Technology (300896.SZ), Bloomage Biotech (688363.SS), Aesthetic Medical Intl (private or unlisted). The cockpit's measured peer set (industry) also includes Alkem Laboratories (ALKEM.NS), China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), Apotex Health (APTX.TO), Oruka Therapeutics (ORKA), Samsung Epis (0126Z0.KS), Belite Bio, Inc. ADR (BLTE).
Is Huadong Medicine expensive compared with its peers?
On forward p/e it trades at 12.5× against a peer median of 21.6×, 3rd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Huadong Medicine stock performed?
Over six months to 18 Nov 2026 the shares returned -18.1% against -1.8% for the median peer; over one year -37.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.